Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer

Fig. 6

PRTN3 expression in peripheral blood cells of patients with mCRC. a Representative data of CD66b/PRTN3 staining of living cells. b Percentage of CD66b expression according to PRTN3 expression (n=12). c Percentage of PRTN3 expression according to CD66b expression (n=12). (d) Correlation between the serum PRTN3 level and the PRTN3-positive neutrophil count (n=12). R=0.3163. P=0.3166. *P<0.05 (e) The relationship between serum PRTN3 levels (the cut-off value is 21.6 ng/ml) and Progression-free survival in the subgroup of 8 patients who received chemotherapy. P=0.043. Abbreviations: mCRC, metastatic colorectal cancer; PRTN3, proteinase-3

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us